TY - JOUR
T1 - COVID-19 infection in patients with haematological disease - A tertiary centre experience from north India
AU - Aggarwal, Mukul
AU - Amjad, Mirza Saleem
AU - Khandelwal, Akash
AU - Kumar, Pradeep
AU - Dhawan, Rishi
AU - Dass, Jasmita
AU - Ganesh, Kumar Vishwanathan
AU - Khanna, Punit
AU - Singh, Akhil Kant
AU - Soni, Kapil Dev
AU - Agarwal, Richa
AU - Bairwa, Mohan
AU - Selvi, Arul
AU - Tyagi, Seema
AU - Seth, Tulika
AU - Mahapatra, Manoranjan
AU - Wig, Naveet
AU - Trikha, Anjan
N1 - Publisher Copyright:
© 2022 Indian Journal of Medical Research, published by Wolters Kluwer - Medknow for Director-General, Indian Council of Medical Research.
PY - 2022/4
Y1 - 2022/4
N2 - This retrospective study was aimed to understand the clinical, laboratory, radiological parameters and the outcome of COVID-19 patients with underlying haematological disease. All patients with known haematological disease admitted with COVID-19-positive status from April to August 2020 in the COVID-19 facility of a tertiary care centre in north India, were included. Their medical records were analyzed for outcome and mortality risk factors. Fifty four patients, 37 males, were included in the study. Of these, 36 patients had haematological malignancy and 18 had benign disorder. Fever (95.5%), cough (59.2%) and dyspnoea (31.4%) were the most common symptoms. Nine patients had severe disease at diagnosis, mostly malignant disorders. Overall mortality rate was 37.0 per cent, with high mortality seen in patients with aplastic anaemia (50.0%), acute myeloid (46.7%) and lymphoblastic leukaemia (40.0%). On univariate analysis, Eastern Cooperative Oncology Group performance status >2 [odd ratio (OR) 11.6], COVID-19 severity (OR 8.2), dyspnoea (OR 5.7) and blood product transfusion (OR 6.4) were the predictors of mortality. However, the presence of moderate or severe COVID-19 (OR 16.6, confidence interval 3.8-72.8) was found significant on multivariate analysis. The results showed that patients with haematological malignancies and aplastic anaemia might be at increased risk of getting severe COVID-19 infection and mortality as compared to the general population.
AB - This retrospective study was aimed to understand the clinical, laboratory, radiological parameters and the outcome of COVID-19 patients with underlying haematological disease. All patients with known haematological disease admitted with COVID-19-positive status from April to August 2020 in the COVID-19 facility of a tertiary care centre in north India, were included. Their medical records were analyzed for outcome and mortality risk factors. Fifty four patients, 37 males, were included in the study. Of these, 36 patients had haematological malignancy and 18 had benign disorder. Fever (95.5%), cough (59.2%) and dyspnoea (31.4%) were the most common symptoms. Nine patients had severe disease at diagnosis, mostly malignant disorders. Overall mortality rate was 37.0 per cent, with high mortality seen in patients with aplastic anaemia (50.0%), acute myeloid (46.7%) and lymphoblastic leukaemia (40.0%). On univariate analysis, Eastern Cooperative Oncology Group performance status >2 [odd ratio (OR) 11.6], COVID-19 severity (OR 8.2), dyspnoea (OR 5.7) and blood product transfusion (OR 6.4) were the predictors of mortality. However, the presence of moderate or severe COVID-19 (OR 16.6, confidence interval 3.8-72.8) was found significant on multivariate analysis. The results showed that patients with haematological malignancies and aplastic anaemia might be at increased risk of getting severe COVID-19 infection and mortality as compared to the general population.
UR - http://www.scopus.com/inward/record.url?scp=85141894278&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85141894278&partnerID=8YFLogxK
U2 - 10.4103/ijmr.ijmr_1180_21
DO - 10.4103/ijmr.ijmr_1180_21
M3 - Article
C2 - 35975348
AN - SCOPUS:85141894278
SN - 0971-5916
VL - 155
SP - 570
EP - 574
JO - Indian Journal of Medical Research
JF - Indian Journal of Medical Research
IS - 5-6
ER -